Regulatory safeguards needed if preimplantation genetic testing for polygenic risk scores (PGT-P) is permitted in Singapore

Author:

Chin Alexis Heng BoonORCID,Lim Lee Wei,Muhsin Sayyed Mohamed

Abstract

Singapore, a highly affluent island city-state located in Southeast Asia, has increasingly leveraged new assisted reproductive technologies (ART) to overcome its dismal fertility rates in recent years. A new frontier in ART is preimplantation genetic testing (PGT) for polygenic risk scores (PRS) to predict complex multifactorial traits in IVF (in vitro fertilisation) embryos, such as type 2 diabetes, cardiovascular diseases and various other characteristics like height, intelligence quotient (IQ), hair and eye colour. Unlike well-known safety risks with human genome editing, there are negligible risks with PGT-P, because there are no man-made genetic modifications that can be transmitted to future generations. Nevertheless, the current efficacy of using PGT-P to select IVF embryos for either increased or decreased probability of developing specific polygenic traits is still far from certain. Hence, the regulatory safeguards proposed here will be based on the assumption that the efficacy of this new technology platform has already been validated. These include: (1) restricting the application of PGT-P only for prevention of clinically relevant polygenic disease traits, (2) securely blocking patients’ access to the raw genomic DNA sequencing data of their IVF embryos, (3) validating diagnosis of polygenic disease traits in the prospective parents/grandparents of IVF embryos, and restricting PGT-P only for preventing specifically diagnosed polygenic disease traits and (4) mandating rigorous and comprehensive genetic counselling for IVF patients considering PGT-P. There is an urgent and dire need to prevent abuse of the PGT-P technique, as well as protect the interests and welfare of patients if its clinical application is to be permitted in the country.

Publisher

BMJ

Reference39 articles.

1. Ng A . Singapore’s total fertility rate drops to historic low of 1.05. Channel News Asia; 2023. Available: https://www.channelnewsasia.com/singapore/singapore-total-fertility-rate-population-births-ageing-parents-children-3301846 [Accessed 7 Apr 2023].

2. Ministry of Health Singapore . New Co-funding scheme and extension of Medisave coverage to support eligible couples in their Parenthood journey. Available: https://www.moh.gov.sg/news-highlights/details/new-co-funding-scheme-and-extension-of-medisave-coverage-to-support-eligible-couples-in-their-parenthood-journey [Accessed 7 Apr 2023].

3. Limitations, concerns and potential: attitudes of Healthcare professionals toward Preimplantation genetic testing using Polygenic risk scores;Siermann;Eur J Hum Genet,2023

4. Whole-genome risk prediction of common diseases in human Preimplantation embryos;Kumar;Nat Med,2022

5. Cao C . Hospital makes history with PGT-P technology. China Daily; 2022. Available: https://www.chinadaily.com.cn/a/202208/11/WS62f47372a310fd2b29e71a4d.html [Accessed 7 Apr 2023].

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3